Abstract：
BACKGROUND: Cutaneous melanoma (CM) is a malignancy with a variable incidence worldwide and a poor advanced-stage prognosis. Melanoma growth is closely associated with the immune system.
METHODS: A cross-sectional study was performed on CM patients admitted at the Hospital de Cancer de Pernambuco (HCP) between 2015 and 2018. Fifty-one CM patients were included, and 30 healthy individuals. The study aimed to evaluate the association of platelet activation mechanisms and inflammatory response in patients with cutaneous melanoma.
RESULTS: Elevated serum IL10 and low serum TNF levels in CM patients compared to controls (p < 0.05). High IL6 levels in patients with negative lymph nodes LN (-) compared to positive lymph nodes group (LN +, p = 0.0005). Low RANTES levels in patients compared to controls (p < 0.05). Elevated levels of platelet-lymphocyte (PLA), platelet-monocytes (PMA), and platelet-neutrophils (PNA) aggregates were observed in patients compared to controls (p < 0.05). CM patients with stage II had lower PMA levels than stages I and III (p < 0.05). High PMA levels were observed in patients with LN (+) compared to the LN (-) group (p < 0.0001). Patients with SSM had high levels of sCD40L and sCD62P compared to controls (p < 0.05)). High sCD40L levels in stage II compared to the stage III group, and sCD62P in stages I and II compared to the stage III group (p < 0.05). High sCD62P levels in patients with LN (-) compared to the group LN (+) (p < 0.05).
CONCLUSIONS: It was observed the immunosuppressive profile in CM may favor tumor progression. High levels of platelet-leukocyte aggregates, sCD40L, and sCD62P may be associated with the worst prognosis.
METHODS: A cross-sectional study was performed on CM patients admitted at the Hospital de Cancer de Pernambuco (HCP) between 2015 and 2018. Fifty-one CM patients were included, and 30 healthy individuals. The study aimed to evaluate the association of platelet activation mechanisms and inflammatory response in patients with cutaneous melanoma.
RESULTS: Elevated serum IL10 and low serum TNF levels in CM patients compared to controls (p < 0.05). High IL6 levels in patients with negative lymph nodes LN (-) compared to positive lymph nodes group (LN +, p = 0.0005). Low RANTES levels in patients compared to controls (p < 0.05). Elevated levels of platelet-lymphocyte (PLA), platelet-monocytes (PMA), and platelet-neutrophils (PNA) aggregates were observed in patients compared to controls (p < 0.05). CM patients with stage II had lower PMA levels than stages I and III (p < 0.05). High PMA levels were observed in patients with LN (+) compared to the LN (-) group (p < 0.0001). Patients with SSM had high levels of sCD40L and sCD62P compared to controls (p < 0.05)). High sCD40L levels in stage II compared to the stage III group, and sCD62P in stages I and II compared to the stage III group (p < 0.05). High sCD62P levels in patients with LN (-) compared to the group LN (+) (p < 0.05).
CONCLUSIONS: It was observed the immunosuppressive profile in CM may favor tumor progression. High levels of platelet-leukocyte aggregates, sCD40L, and sCD62P may be associated with the worst prognosis.
摘要：
背景：皮肤黑素瘤（CM）是一种在全球范围内发病率可变且晚期预后较差的恶性肿瘤。黑色素瘤的生长与免疫系统密切相关。
方法：对2015年至2018年在伯南布哥癌症医院（HCP）收治的CM患者进行了横断面研究。纳入51例CM患者，30个健康的人该研究旨在评估皮肤黑色素瘤患者的血小板活化机制与炎症反应的关系。
结果：与对照组相比，CM患者血清IL10升高，血清TNF水平降低（p<0.05）。与淋巴结阳性组相比，淋巴结阴性LN（-）患者的IL6水平较高（LN+，p=0.0005)。与对照组相比，患者的RANTES水平较低（p<0.05）。血小板淋巴细胞（PLA）水平升高，血小板单核细胞（PMA），与对照组相比，在患者中观察到血小板-中性粒细胞（PNA）聚集体（p<0.05）。II期CM患者的PMA水平低于I期和III期（p<0.05）。与LN（-）组相比，在LN（+）患者中观察到高PMA水平（p<0.0001）。与对照组相比,SSM患者具有高水平的sCD40L和sCD62P(p<0.05))。与III期相比，II期sCD40L水平较高，Ⅰ期和Ⅱ期的sCD62P与Ⅲ期组比拟(p<0.05)。与LN组(+)相比,LN组患者sCD62P水平较高(p<0.05)。
结论：观察到CM中的免疫抑制谱可能有利于肿瘤进展。高水平的血小板-白细胞聚集体，sCD40L,sCD62P可能与不良预后相关。
方法：对2015年至2018年在伯南布哥癌症医院（HCP）收治的CM患者进行了横断面研究。纳入51例CM患者，30个健康的人该研究旨在评估皮肤黑色素瘤患者的血小板活化机制与炎症反应的关系。
结果：与对照组相比，CM患者血清IL10升高，血清TNF水平降低（p<0.05）。与淋巴结阳性组相比，淋巴结阴性LN（-）患者的IL6水平较高（LN+，p=0.0005)。与对照组相比，患者的RANTES水平较低（p<0.05）。血小板淋巴细胞（PLA）水平升高，血小板单核细胞（PMA），与对照组相比，在患者中观察到血小板-中性粒细胞（PNA）聚集体（p<0.05）。II期CM患者的PMA水平低于I期和III期（p<0.05）。与LN（-）组相比，在LN（+）患者中观察到高PMA水平（p<0.0001）。与对照组相比,SSM患者具有高水平的sCD40L和sCD62P(p<0.05))。与III期相比，II期sCD40L水平较高，Ⅰ期和Ⅱ期的sCD62P与Ⅲ期组比拟(p<0.05)。与LN组(+)相比,LN组患者sCD62P水平较高(p<0.05)。
结论：观察到CM中的免疫抑制谱可能有利于肿瘤进展。高水平的血小板-白细胞聚集体，sCD40L,sCD62P可能与不良预后相关。
